+

WO1995029711A1 - Enveloppe excluant les cellules pour greffes vasculaires - Google Patents

Enveloppe excluant les cellules pour greffes vasculaires Download PDF

Info

Publication number
WO1995029711A1
WO1995029711A1 PCT/US1995/004687 US9504687W WO9529711A1 WO 1995029711 A1 WO1995029711 A1 WO 1995029711A1 US 9504687 W US9504687 W US 9504687W WO 9529711 A1 WO9529711 A1 WO 9529711A1
Authority
WO
WIPO (PCT)
Prior art keywords
sheath
blood vessel
macromolecules
polymeric material
microporous polymeric
Prior art date
Application number
PCT/US1995/004687
Other languages
English (en)
Inventor
William Carl Bruchman
Anita Jean Switzer
Original Assignee
W.L. Gore & Associates, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by W.L. Gore & Associates, Inc. filed Critical W.L. Gore & Associates, Inc.
Priority to AU22928/95A priority Critical patent/AU2292895A/en
Priority to EP95916422A priority patent/EP0757561A1/fr
Priority to JP7528270A priority patent/JPH09512456A/ja
Publication of WO1995029711A1 publication Critical patent/WO1995029711A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels

Definitions

  • the present invention relates to vascular prostheses improved through the use of an external sheath that is resistant to cell ingrowth while being permeable to flux of fluid and macromolecules across the thickness of the sheath.
  • the sheath can also impart mechanical strength to the vascular tissue of the prostheses.
  • the practice of grafting with allogeneic arteries was abandoned in favor of the mechanically superior alternative of using vascular grafts made of synthetic materials.
  • the synthetic materials principally used for this grafting are polyethylene terephthalate and expanded polytetrafluoroethylene (ePTFE). These materials offer biocompatibility and provide sufficient mechanical integrity to prevent aneurysmal dilation. Prosthetics made of these materials were shown to be successful in the replacement of large vessels such as the aorta or iliac arteries and are still successfully used in these applications. Although successful when used in large diameter applications, the patency performance of these materials in demanding small diameter applications such as coronary artery bypass or peripheral arterial bypass distal to the popliteal artery, for example, has been substantially less than that of transplanted living autologous vessels.
  • Low porosity ePTFE grafts with a short fibril length (10 ⁇ m) had layers of tissue on either side of the graft wall, but no ingrowth of tissue into the interstices of the graft. These low porosity grafts were 67% patent at six months postoperatively. (Florian et al., "Small Vessel Replacement With Gore-tex (Expanded Polytetrafluoroethylene)," Arch. Surg. 111 :267-270 (1976))
  • the present invention is directed to improved vascular prostheses derived from donor blood vessels. It is an object of the present invention to provide improved performance for vascular prostheses by preventing many of the failures that are a consequence of the invasion of an implant by host cells. It is a further object of the present invention to provide improved performance for vascular prostheses by providing a cell excluding covering for the vascular tissue of a prosthesis that permits exchange of biological fluids and substances across the vascular tissue of the implant and the perigraft tissue of a recipient.
  • the present invention is a covering for a blood vessel which comprises a sheath surrounding the blood vessel, wherein the sheath comprises a microporous polymeric material and wherein the sheath serves as a barrier to external cellular contact to the blood vessel, while being permeable to macromolecules.
  • Figure 1 is a cross-sectional view of a mammalian artery (2) having the external sheath (1) applied thereto;
  • Figure 2 is another view of the embodiment of the present invention illustrated in Figure 1.
  • the present invention is directed to a sheath for use in vascular prostheses derived from donor blood vessels, particularly mammalian blood vessels.
  • a vascular prosthesis may employ an external sheath of the present invention around a donor blood vessel.
  • the sheath prevents access to the donor vessel wall by host cells originating from perigraft tissue. While resisting host cell ingrowth, the external sheath is permeable to the flux of macromolecules across its thickness.
  • the exclusion of host cells by the external sheath and the bi-directional flow of macromolecules through the external sheath assists in maintaining the original function of the underlying donor vascular tissue of the prosthesis.
  • the term "macromolecules" is understood to include, but not be limited to, molecules having a molecular weight up to and including about 2,000,000 MW.
  • the original architecture and function of vessel derived vascular grafts can be maintained if invasion of the donor vessel wall by host cells is prevented while the flux of macromolecules across the wall is permitted. If the original architecture and function of the arterial wall of a vascular graft is so maintained, many of the failures previously noted with transplanted vessels can be prevented, resulting in improved patency performance of these biologically derived grafts.
  • the teachings of the present invention are thus directly opposite those of the prior art in this field regarding the desirability of host cell ingrowth into the donor tissue of a biological vascular graft.
  • FIG. 1 A structure resembling this configuration is shown in Figures 1 and 2.
  • the sheath (1) is applied to the external surface of a mammalian blood vessel (2) forming a tubular vascular graft (3).
  • the flux of macromolecules across the thickness of the external sheath is achieved by constructing the sheath of materials that are permeable to macromolecules while being resistant to cell ingrowth.
  • the preferred materials for construction of the external sheath are synthetic materials that are microporous.
  • Suitable materials for construction of the external sheath of the present invention include, but are not limited to, the group of polymer materials with demonstrated biocompatibility and stability under implant conditions, such as, polytetrafluoroethylene (PTFE), polyethylene terepthalate, fluorinated ethylene propylene (FEP), polyethylene, polypropylene, and siloxane, for example.
  • PTFE polytetrafluoroethylene
  • FEP fluorinated ethylene propylene
  • the external sheath employed in the preferred embodiment of the present invention is made of expanded PTFE (ePTFE) as produced in U.S. Patent 3,953,566, issued to Gore, which is incorporated herein by reference.
  • the pore size that is effective in resisting cell ingrowth across the thickness of the sheath is dependent upon the thickness of the wall itself and the tortuosity of the pores connecting the outer surface with the inner surface of the sheath. In the case of regular uniform pores in a thin sheath construction (about 10-20 ⁇ m in thickness) the pores should be selected to be less than about 3 ⁇ m. This value is based upon Boyden chamber migration assays where the limit of fibroblast invasion of straight, uniform pores is about 5-8 ⁇ m and the limit of leukocyte invasion through straight, uniform pores is about 3-5 ⁇ m. (A. Albini et al., "Fibroblast Chemotaxis," Collagen Rel. Res. 5:283-296, (1985); W. Morzycki et al., "Tumor Necrosis Factor-alpha but not Interleukin-1 Induces Polymorphonuclear Leucocyte Migration Through
  • Fibroblast Layers by a Fibroblast-Dependent Mechanism Immunology, 74:107-113, (1991)
  • the individual pores can be somewhat larger and still serve as an effective barrier to the passage of cells across the layer.
  • the pore size of the sheath is related to the fibril length of the sheath material and the thickness of the sheath material. Thicker fibrillated sheath materials generally have more tortuous pathways connecting one end of a pore to the other end of the pore.
  • a thicker fibrillated sheath may have pores that are larger than invading cells, but will remain resistant to cell ingrowth due to the increased tortuosity of the pathways of the pores in thicker sheath material.
  • the fibril length should be chosen to form pores that resists cellular access through the sheath, while being permeable to macromolecules.
  • the fibril length of porous ePTFE that has been expanded in a single direction is defined herein as the average of ten measurements between nodes connected by fibrils in the direction of expansion.
  • Ten measurements are made in the following manner. First, a photomicrograph is made of a representative portion of the sample surface, of adequate magnification to show at least five sequential fibrils within the length of the photomicrograph. Two parallel lines are drawn across the length of the photomicrograph so as to divide the photograph into three equal areas, with the lines being drawn in the direction of expansion and parallel to the direction of orientation of the fibrils.
  • the fibril length is estimated by examining a representative photomicrograph of the material surface and comparing fibril lengths as described above in a manner that represents the various directional orientations of the fibrils.
  • the sheath may be constructed in a tubular configuration and applied to the external surface of a stabilized artery .
  • An external sheath can also be applied as a film to the outside of a donor blood vessel, and the film layers subsequently bonded together.
  • the permeability characteristics of the sheath can be evaluated by testing with markers of known size, such as dextrans and polystyrene microspheres.
  • dextran with an average molecular weight of about 2,000,000 MW, labelled with the colored compound fluorescein (Sigma Chemical Co., St. Louis, MO), can be used to test the ability of the sheath to pass macromolecules.
  • Cell impermeability of the sheath can be tested using polystyrene microspheres with a diameter of about 3 ⁇ m (Polysciences, Inc., Wa ⁇ ington, PA) at a concentration of about 2.5% solids in suspension, for example.
  • the markers are suspended as an aqueous solution or as an aqueous suspension at concentrations sufficient to provide a distinctly visible color.
  • the preferred concentration of the fluorescein-labeled dextran solution is approximately 0.2 mg dextran/ml.
  • the preferred concentration of the suspension of the polystyrene microspheres is approximately 0.02 ml microspheres/ml suspension, to yield about 4.5 x 107 beads/ml suspension.
  • the evaluation of the sheath permeability occurs at about 23°C.
  • the sheath is prepared for permeability testing by rendering it permeable to water, if necessary. For example, sheaths constructed of ePTFE are wetted with 100% ethyl alcohol and then flushed with water to remove the alcohol before permeability testing.
  • the dextran test solution is instilled in the lumen of a sheath and pressurized to about 20.7 kPa using a syringe.
  • the contents of the syringe are forced through the sheath and the liquid that filters through the sheath wall is collected and visually inspected against a white background for evidence of the colored dextran.
  • the number of microspheres in the suspension are determined by using an appropriate counting device, such as a hemacytometer, for example.
  • the permeability of the sheath is then tested by forcing the microsphere-containing suspension through the sheath material at about 20.7 kPa using a syringe.
  • the syringe is refilled with water and the water also forced through the sheath at about 20.7 kPa.
  • the liquid that filters through the sheath wall is collected and subjected to centrifugation at about 300 x g for about 5-10 minutes.
  • the supernatant is decanted and discarded and the pellet of microspheres is resuspended in a known volume of water.
  • the number of microspheres in the resuspended pellet are counted and compared with the original suspension.
  • the number of microspheres that pass through the sheath are expressed as a percentage of the number introduced into the lumen of the sheath.
  • An appropriate sheath for use in the present invention will pass the about 2,000,000 MW dextran at pressures at or below about 20.7 kPa so that the colored solution that filters through the sheath is clearly visible when viewed against a white background. Additionally, the sheath will not allow more than about 5% of the 3 ⁇ m microspheres to pass across its thickness at a pressure of about 20.7 kPa.
  • the sheath of the present invention can also function as a component of a vascular prosthesis that supplies mechanical reinforcement for the prosthesis. While a biologic component of the graft, such as a donor blood vessel, supplies the antithrombotic properties to the vascular prosthesis, the long term mechanical stability is usually supplied by the sheath component. Accordingly, the sheath of the present invention is selected to provide mechanical strength necessary for the particular diameter of the graft used in order to resist the hoop stress induced by blood pressure, to provide sufficient mechanical strength for creating anastomoses, and to resist anastomotic stresses.
  • the sheath is constructed by wrapping a mandrel with multiple layers of ePTFE film, such as those described in U.S. Patent 3,953,566 and 4,187,390, both issued to Gore, each of which is incorporated herein by reference, and adhering the film to itself by heating the film and mandrel in an oven at about 380°C for about 10 to about 20 minutes.
  • the film tube is removed from the mandrel and prepared tissue graft installed in the lumen of the polymeric tube.
  • Other materials, or combinations of materials may be applied to the tissue tube similarly, using temperatures and times appropriate for the physical properties of the chosen material.
  • sheath material Other methods include placing a processed artery onto a mandrel and wrapping the artery with multiple layers of an ePTFE and FEP composite film, and heating the film layer very briefly from about 310°C to about 350°C to adhere the film wrap to itself on the outer surface of the vessel.
  • the FEP-coated ePTFE film is made by a process which includes the steps of: a) contacting a porous PTFE substrate, usually in the form of a membrane or film, with another layer which is preferably a film of FEP or alternatively of another thermoplastic polymer; b) heating the composition obtained in step (a) to a temperature above the melting point of the thermoplastic polymer; c) stretching the heated composition of step (b) while maintaining the temperature above the melting point of the thermoplastic polymer; and d) cooling the product of step (c).
  • Another sheath construction method is the fabrication of a tubular form of ePTFE constructed according to U.S. Patent 3,593,566 to Gore using a uniaxial expansion.
  • the processed blood vessel is inserted into the ePTFE tube so constructed.
  • the tubular form must be permeable to the passage of macromolecules but exclude the passage of cells.
  • a sheath tube was constructed from a porous expanded polytetrafluoroethylene (ePTFE) film.
  • ePTFE porous expanded polytetrafluoroethylene
  • This porous ePTFE film had a microstructure of nodes interconnected by fibrils.
  • the film was made by expansion by stretching in a single direction, which was the direction in which the resulting fibrils were primarily oriented.
  • the film used in the preparation of this invention had a fibril length of about 50 ⁇ m, a density of about 0.3 g/cm, a thickness of about 0.01 mm, and were 86% porous by bulk volume.
  • the fibril length of the porous ePTFE film referred to above was an estimated mean value obtained by examining a scanning electron photomicrograph of the film.
  • the film was applied to a metal mandrel about 5 mm in diameter by wrapping the mandrel with the film in a helical manner.
  • the pitch of the helix was such that each wrap of film overlapped approximately two-thirds of the previous wrap.
  • the mandrel was wrapped three times in this fashion, resulting in a film tube constructed of about nine layers of film.
  • the wrapped mandrel was then heated in a oven at about 378°C for seven minutes to adhere the film layers together.
  • the mandrel was removed from the oven and allowed to cool. Once cool, the film sheath was removed from the mandrel.
  • the sheath was tested for ability to pass macromolecules as follows.
  • a solution of fluorescein-labeled dextran with an average molecular weight of 2,000,000 MW was prepared in water at a concentration of about 0.2 mg/ml.
  • a portion of the sheath, about 10 cm in length, was mounted on a barbed Luer fitting and wetted with 100% ethyl alcohol.
  • the alcohol was removed by flushing the sheath with water using a syringe to force the water through the pores of the sheath.
  • the dextran test solution was instilled in the lumen of the sheath and pressurized to about 20.7 kPa.
  • the contents of the syringe were forced through the sheath and the liquid that filtered through the sheath wall was collected and visually inspected against a white background for evidence of the colored dextran.
  • the solution was distinctly yellow colored, and the sheath, therefore, permeable to macromolecules.
  • the sheath was tested for ability to prevent cellular infiltration.
  • a second 10 cm length of sheath was wetted with ethyl alcohol and the alcohol replaced with water as described above.
  • Microspheres about 3 ⁇ m in diameter (Polysciences, Warrington, PA) were used to determine the ability of the sheath to prevent cellular infiltration.
  • a stock suspension of microspheres was prepared. The number of microspheres in the suspension was determined to be about 4.7 x 107 spheres/ml using a hemacytometer.
  • the microsphere-containing suspension was tested by forcing the contents of the syringe, 5 ml of stock suspension, through the sheath material at 20.7 kPa.
  • the syringe was refilled with water and the water also forced through the sheath at 20.7 kPa.
  • the liquid that filtered through the sheath wall was collected and subjected to centrifugation at about 300 x g for 5 minutes.
  • the supernatant was decanted and discarded, and the pellet of microspheres was resuspended in one ml of water.
  • the number of microspheres in the resuspended pellet was counted as for the original suspension and the count expressed as a percentage of the number of microspheres used for the test.
  • the percentage of microspheres passing through the wall of the sheath was 0.17%.
  • the sheath can be considered resistant to cell ingrowth since less than 5% of the microspheres pass through the sheath wall.
  • a sheath of porous ePTFE was constructed.
  • the sheath was permeable to macromolecules and resistant to cellular infiltration by the defining tests.
  • the sheath can be installed onto arterial replacement grafts comprised of tissue from allogeneic or xenogeneic sources by sliding the processed artery into the lumen of the sheath.
  • DMSO/HBSS Hanks' Balanced Salt Solution
  • the arteries were rinsed thoroughly in HBSS and were sleeved with a 5 mm tube and pressure fixed in 0.25% glutaraldehyde in 0.020 M N- 2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (HEPES) , pH 7.3, with 0.44% NaCl and 0.26% MgCh-6H2 ⁇ , at about 27.6 kPa for about 2 hours.
  • the arteries were then removed from their sleeves and left immersed in the fixing solution overnight. After fixing, the arteries were rinsed thoroughly in normal saline and sleeved with the sheath from Example 1.
  • the finished wall thickness of the sleeved digested artery was 0.14 mm while the finished wall thickness of the sleeved control artery was 0.22 mm.
  • arteries Arteries of an appropriate size to provide a finished internal diameter of approximately 4 mm were selected.
  • the arteries were sleeved with 5 mm GORE- TEX® Vascular Graft (W. L. Gore & Associates, Inc., Flagstaff, AZ), mounted on barbed Luer fittings and were pressure fixed at about 27.6 kPa for 2 hours in 2.5% glutaraldehyde in 0.2 M Sorenson's phosphate buffer, pH 7.0. Fixation occurred at about 23°C. After fixation, the arteries were rinsed in normal saline, and stored in normal saline at about 4°C until required for use.
  • the sheath to the fixed arteries was performed as follows.
  • the artery was placed onto a 3 mm diameter mandrel and the ends of the artery secured with wire ties.
  • a helical wrap of 25.4 mm wide film was applied over the outer surface of the arteries.
  • the film used for the helical wrapping was a porous ePTFE film with an additional layer or coating of fluorinated ethylene propylene (FEP) on one surface.
  • FEP fluorinated ethylene propylene
  • the FEP-coated porous ePTFE film was made by a process which comprises the steps of : a) contacting a porous ePTFE substrate, usually in the form of a membrane or film, with another layer which is preferably a film of FEP or alternatively of another thermoplastic polymer; b) heating the composition obtained in step (a) to a temperature above the melting point of the thermoplastic polymer; c) stretching the heated composition of step (b) while maintaining the temperature above the melting point of the thermoplastic polymer; and d) cooling the product of step (c).
  • the FEP coating of the porous ePTFE film for this example was discontinuous, thereby resulting in a porous composite film.
  • the porous FEP-coated ePTFE film used to make this example had a thickness of about 0.03 mm, a density of about 0.3 g/cc, a fibril length of about 40 ⁇ m, and a width of about 25.4 mm.
  • the FEP-coated side of the film was placed against the fixed arterial tissue.
  • the pitch of the helical wrap was chosen such that each wrap of the film overlapped approximately two-thirds of the prior wrap.
  • the arteries were wrapped three times in this fashion, resulting in a film layer constructed from about nine layers of film.
  • the film-wrapped arteries were contacted very briefly by an aluminum fixture heated to about 350°C to thermally bond the layers of film together while minimizing the heating of the fixed artery.
  • the fixture was an aluminum ring with an internal diameter of about 0.8 cm, a wall thickness of about 1.5 cm and an overall length of about 5 cm.
  • the process employed to bond the film layers was to place the wrapped artery through the hole in the fixture, contact the surface of the film to the heated fixture and rotate the graft assembly.
  • One revolution of a graft with an outside diameter of about 5 mm was performed in 1.5 to 2.0 seconds.
  • the wire ties attaching the artery to the mandrel were removed and the fixed artery with the sheath applied removed from the mandrel.
  • the artery-sheath composite was stored in normal saline or water until permeability testing of the sheath could be performed.
  • the sheath was removed from the artery and the artery discarded.
  • the sheath was tested for ability to pass macromolecules and to prevent cellular infiltration as described in Example 1.
  • the sheath when prefreated by wetted with 100% ethyl alcohol, readily passed the 2,000,000 MW dextran, indicating that a sheath constructed in this fashion was permeable to macromolecules.
  • the same sheath allowed no measurable quantity of the 3 ⁇ m microspheres to pass through, indicating that this sheath construction is resistant to cellular infiltration.
  • One artery of the pair was sleeved with the sheath described in Example 1. The other was unsleeved. Testing occurred at about 23°C. To test, each artery was slipped over a segment of latex tubing and one end of the tubing and graft assembly connected to a pressure source. The tubing was filled with water and the other end of the assembly clamped with a hemostat. The water pressure inside the tubing was increased at about 69 kPa/sec until the graft ruptured. The pressure at which rupture occurred was recorded.
  • Permeability of the sheath of the present invention to macromolecules, while being resistant to host cell ingrowth is a necessary element in providing improved patency performance of donor blood vessels.
  • permeable and impermeable sheaths were constructed from ePTFE tubing prepared as described in U.S. Patent 3,953,566, issued to Gore, which is incorporated herein by reference.
  • the tubing had a mean fibril length of 5 ⁇ m, an internal diameter of about 5 mm, and a wall thickness of about 0.48 mm.
  • the tubing was cut into segments about 10 cm in length. Half of the segments were rendered impermeable by wetting the tubing with 1,1,2 trichloro- 1,2,2- trifluoroethane (Freon TF, E.I. duPont de Nemours, Inc., Wilmington, DE) and infiltrating the pores of the tubing with a 50% (approximate) (v:v) mixture of 1,1,2 trichloro- 1, 2,2- trifluoroethane and Silastic Type A Medical Grade Adhesive (Dow Corning, Inc., Midland, MI).
  • the tubing was then placed on a 5 mm diameter mandrel and additional unthinned adhesive was applied to the outer surface of the tubing. The tubing was placed in a forced air oven at about 100°C for approximately two hours to cure the adhesive. Both the impermeable tubing and a section of untreated ePTFE tubing were cut to 5 cm and sterilized by autoclave.
  • a 6 cm length of both femoral arteries was removed and the arterial branches ligated with silk ligatures.
  • Each artery was placed in 15% DMSO in HBSS and frozen in liquid nitrogen for 15 days.
  • the arteries were prepared for implantation into a recipient greyhound dog by first thawing the frozen arteries.
  • the arteries were rapidly thawed by immersing the freezing tubes containing the arteries in 37 ⁇ C water.
  • the arteries were rinsed in saline and the adventitia trimmed.
  • One end of each artery was attached to a barbed Luer fitting and the arteries sleeved with a segment of 5 mm GORE-TEX® Vascular Graft (W. L.
  • the arteries were immersed in 500 ml of sterile normal saline to remove the excess glutaraldehyde, and stirred at room temperature for 15 minutes, at which time the saline was replaced with 500 ml of fresh sterile normal saline.
  • the arteries were rinsed for an additional 15 minutes in the fresh sterile saline.
  • the arteries were stored in fresh sterile normal saline until required for implantation.
  • each fixed artery segment was placed within the lumen of one of the sterile sheaths previously prepared.
  • the ends of the fixed arteries were cut flush with the ends of the sheaths.
  • the composite grafts so constructed were about 5 cm in length.
  • the femoral arteries of a recipient greyhound dog were surgically exposed and a segment of about 5 cm excised from both femoral arteries.
  • Each graft was surgically interposed into one of the femoral arteries using end-to-end technique and a continuous suture.
  • Both layers of the composite grafts were anastomosed to the host femoral arteries with CV-6 GORE-TEX® Suture (W. L. Gore & Associates, Inc., Flagstaff, AZ).
  • the femoral artery replaced with a processed artery covered with the impermeable sheath was found to be occluded by duplex scanner ultrasonography. Occlusion was confirmed at 20 days postoperation with contrast arteriography.
  • the remaining femoral artery replaced with a processed artery covered with a permeable sheath of the present invention was visualized using arteriography and was found to be patent.
  • the fixed graft with the impermeable sheath was found occluded at 19 days after implantation, while the graft with the selectively permeable sheath of the present invention remained patent for at least 60 days, at which time the grafts were explanted and the patent graft subjected to histological studies. Histological examination of the patent graft showed the inner layers of the biologic component of the patent graft had maintained the architecture of the original donor artery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Enveloppe destinée à être utilisée avec des prothèses vasculaires provenant de vaisseaux sanguins prélevés sur un donneur, et notamment de vaisseaux sanguins de mammifère. Une prothèse vasculaire de cette invention utilise une enveloppe extérieure placée autour du vaisseau sanguin donné. Cette enveloppe empêche les cellules hôtes issues des tissus entourant la greffe d'accéder à la paroi du vaisseau donné, elle ne laisse pas passer les cellules hôtes mais est cependant perméable au flux de macromolécules qui peuvent traverser son épaisseur. L'exclusion des cellules hôtes par l'enveloppe extérieure et l'écoulement bidirectionnel des macromolécules à travers son épaisseur aident à maintenir la fonction originelle des tissus vasculaires donnés sous-jacents de la prothèse.
PCT/US1995/004687 1994-04-29 1995-04-17 Enveloppe excluant les cellules pour greffes vasculaires WO1995029711A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU22928/95A AU2292895A (en) 1994-04-29 1995-04-17 Cell excluding sheath for vascular grafts
EP95916422A EP0757561A1 (fr) 1994-04-29 1995-04-17 Enveloppe excluant les cellules pour greffes vasculaires
JP7528270A JPH09512456A (ja) 1994-04-29 1995-04-17 人工血管のための細胞排除性鞘

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/235,071 1994-04-29
US08/235,071 US5584876A (en) 1994-04-29 1994-04-29 Cell excluding sheath for vascular grafts

Publications (1)

Publication Number Publication Date
WO1995029711A1 true WO1995029711A1 (fr) 1995-11-09

Family

ID=22883986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/004687 WO1995029711A1 (fr) 1994-04-29 1995-04-17 Enveloppe excluant les cellules pour greffes vasculaires

Country Status (6)

Country Link
US (1) US5584876A (fr)
EP (1) EP0757561A1 (fr)
JP (1) JPH09512456A (fr)
AU (1) AU2292895A (fr)
CA (1) CA2186373A1 (fr)
WO (1) WO1995029711A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244271B2 (en) 1996-01-22 2007-07-17 Boston Scientific Scimed, Inc. Self-sealing PTFE vascular graft and manufacturing methods

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5941908A (en) * 1997-04-23 1999-08-24 Vascular Science, Inc. Artificial medical graft with a releasable retainer
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US8527026B2 (en) 1997-03-04 2013-09-03 Dexcom, Inc. Device and method for determining analyte levels
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US6254627B1 (en) * 1997-09-23 2001-07-03 Diseno Y Desarrollo Medico S.A. De C.V. Non-thrombogenic stent jacket
US6468300B1 (en) 1997-09-23 2002-10-22 Diseno Y Desarrollo Medico, S.A. De C.V. Stent covered heterologous tissue
US6371982B2 (en) 1997-10-09 2002-04-16 St. Jude Medical Cardiovascular Group, Inc. Graft structures with compliance gradients
US6048362A (en) * 1998-01-12 2000-04-11 St. Jude Medical Cardiovascular Group, Inc. Fluoroscopically-visible flexible graft structures
US6235054B1 (en) 1998-02-27 2001-05-22 St. Jude Medical Cardiovascular Group, Inc. Grafts with suture connectors
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US20040126404A1 (en) * 1998-08-21 2004-07-01 University Of Queensland Of St. Lucia Implant material
EP1123122B1 (fr) * 1998-08-21 2008-01-02 The University Of Queensland Materiau pour implant
WO2000048530A1 (fr) * 1999-02-16 2000-08-24 Talison Research, Inc. Greffon vasculaire multicouche et multifonction
US6334868B1 (en) 1999-10-08 2002-01-01 Advanced Cardiovascular Systems, Inc. Stent cover
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US6761700B2 (en) 2001-02-09 2004-07-13 Orqis Medical Corporation Extra-corporeal vascular conduit
AU2002309528A1 (en) 2001-04-02 2002-10-15 Therasense, Inc. Blood glucose tracking apparatus and methods
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US7379765B2 (en) 2003-07-25 2008-05-27 Dexcom, Inc. Oxygen enhancing membrane systems for implantable devices
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8364229B2 (en) * 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US7828728B2 (en) 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
US9282925B2 (en) 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US20040126405A1 (en) * 2002-12-30 2004-07-01 Scimed Life Systems, Inc. Engineered scaffolds for promoting growth of cells
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
JP4692902B2 (ja) * 2003-04-28 2011-06-01 キップス・ベイ・メディカル・インコーポレーテッド 柔軟な静脈移植体
US7998188B2 (en) 2003-04-28 2011-08-16 Kips Bay Medical, Inc. Compliant blood vessel graft
US20050131520A1 (en) * 2003-04-28 2005-06-16 Zilla Peter P. Compliant blood vessel graft
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US7761130B2 (en) 2003-07-25 2010-07-20 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US8622905B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. System and methods for processing analyte sensor data
US6931327B2 (en) 2003-08-01 2005-08-16 Dexcom, Inc. System and methods for processing analyte sensor data
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
ATE480761T1 (de) 2003-12-05 2010-09-15 Dexcom Inc Kalibrationsmethoden für einen kontinuierlich arbeitenden analytsensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8774886B2 (en) 2006-10-04 2014-07-08 Dexcom, Inc. Analyte sensor
EP2316331B1 (fr) 2003-12-09 2016-06-29 Dexcom, Inc. Traitement de signal pour capteur d'analyte continu
US7364592B2 (en) * 2004-02-12 2008-04-29 Dexcom, Inc. Biointerface membrane with macro-and micro-architecture
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US7857760B2 (en) 2004-07-13 2010-12-28 Dexcom, Inc. Analyte sensor
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US7641688B2 (en) * 2004-09-16 2010-01-05 Evera Medical, Inc. Tissue augmentation device
US8029563B2 (en) 2004-11-29 2011-10-04 Gore Enterprise Holdings, Inc. Implantable devices with reduced needle puncture site leakage
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
US8060174B2 (en) 2005-04-15 2011-11-15 Dexcom, Inc. Analyte sensing biointerface
US8163002B2 (en) * 2005-11-14 2012-04-24 Vascular Devices Llc Self-sealing vascular graft
EP3513708B1 (fr) 2006-03-09 2022-12-28 Dexcom, Inc. Systèmes et procédés de traitement de données de capteur de substance à analyser
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US20200037875A1 (en) 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US8562558B2 (en) 2007-06-08 2013-10-22 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
EP4159114B1 (fr) 2007-10-09 2024-04-10 DexCom, Inc. Système d'administration d'insuline intégré avec un capteur de glucose en continu
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
US8229535B2 (en) 2008-02-21 2012-07-24 Dexcom, Inc. Systems and methods for blood glucose monitoring and alert delivery
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP3795987B1 (fr) 2008-09-19 2023-10-25 Dexcom, Inc. Membrane contenant des particules et électrode particulaire pour capteurs d analytes
US9149220B2 (en) 2011-04-15 2015-10-06 Dexcom, Inc. Advanced analyte sensor calibration and error detection
WO2010058406A1 (fr) 2008-11-24 2010-05-27 Vascular Graft Solutions Ltd. Stent externe
US10052218B2 (en) 2011-04-18 2018-08-21 Vascular Graft Solutions Ltd. Devices and methods for deploying implantable sleeves over blood vessels
US9814560B2 (en) 2013-12-05 2017-11-14 W. L. Gore & Associates, Inc. Tapered implantable device and methods for making such devices
US10357385B2 (en) 2015-06-05 2019-07-23 W. L. Gore & Associates, Inc. Low bleed implantable prosthesis with a taper
CN212438615U (zh) 2017-10-24 2021-02-02 德克斯康公司 可穿戴设备
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033234A (en) * 1978-10-12 1980-05-21 Sumitomo Electric Industries Tubular organic prosthesis and a process for the production thereof
DE3918736A1 (de) * 1989-06-08 1990-12-13 Christian Dr Vallbracht Kunststoffueberzogene metallgitterstents
WO1991007145A1 (fr) * 1989-11-22 1991-05-30 Indu Kapadia Ligament prosthetique
EP0448840A2 (fr) * 1990-02-26 1991-10-02 American Cyanamid Company Dispositif pour obturer les plaies à base d'un filament composite
WO1992022604A1 (fr) * 1991-06-14 1992-12-23 W.L. Gore & Associates, Inc. Polytetrafluorethylene expanse poreux a modification de surface, et procede de fabrication
WO1993018214A1 (fr) * 1992-03-13 1993-09-16 Atrium Medical Corporation Produits en polytetrafluoroethylene expanse a porosite regulee et leur fabrication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3626947A (en) * 1970-02-19 1971-12-14 Charles Howard Sparks Method and apparatus for vein and artery reenforcement
SE392582B (sv) * 1970-05-21 1977-04-04 Gore & Ass Forfarande vid framstellning av ett porost material, genom expandering och streckning av en tetrafluoretenpolymer framstelld i ett pastabildande strengsprutningsforfarande
US3974526A (en) * 1973-07-06 1976-08-17 Dardik Irving I Vascular prostheses and process for producing the same
JPS6037735B2 (ja) * 1978-10-18 1985-08-28 住友電気工業株式会社 人工血管
WO1982000091A1 (fr) * 1980-07-01 1982-01-21 V Ketharanathan Protheses vasculaires
US4482516A (en) * 1982-09-10 1984-11-13 W. L. Gore & Associates, Inc. Process for producing a high strength porous polytetrafluoroethylene product having a coarse microstructure
US4816339A (en) * 1987-04-28 1989-03-28 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US4911717A (en) * 1987-06-18 1990-03-27 Gaskill Iii Harold V Intravasular artificial organ
WO1989010099A1 (fr) * 1988-04-21 1989-11-02 Uab Research Foundation Materiaux bioelastomeres adaptes pour empecher que des adherences ne se produisent sur des sites de reparation de blessure
US5100422A (en) * 1989-05-26 1992-03-31 Impra, Inc. Blood vessel patch
US5084065A (en) * 1989-07-10 1992-01-28 Corvita Corporation Reinforced graft assembly
US5348788A (en) * 1991-01-30 1994-09-20 Interpore Orthopaedics, Inc. Mesh sheet with microscopic projections and holes
US5229045A (en) * 1991-09-18 1993-07-20 Kontron Instruments Inc. Process for making porous membranes
US5429821A (en) * 1992-05-29 1995-07-04 The Regents Of The University Of California Non-fibrogenic high mannuronate alginate coated transplants, processes for their manufacture, and methods for their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033234A (en) * 1978-10-12 1980-05-21 Sumitomo Electric Industries Tubular organic prosthesis and a process for the production thereof
DE3918736A1 (de) * 1989-06-08 1990-12-13 Christian Dr Vallbracht Kunststoffueberzogene metallgitterstents
WO1991007145A1 (fr) * 1989-11-22 1991-05-30 Indu Kapadia Ligament prosthetique
EP0448840A2 (fr) * 1990-02-26 1991-10-02 American Cyanamid Company Dispositif pour obturer les plaies à base d'un filament composite
WO1992022604A1 (fr) * 1991-06-14 1992-12-23 W.L. Gore & Associates, Inc. Polytetrafluorethylene expanse poreux a modification de surface, et procede de fabrication
WO1993018214A1 (fr) * 1992-03-13 1993-09-16 Atrium Medical Corporation Produits en polytetrafluoroethylene expanse a porosite regulee et leur fabrication

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244271B2 (en) 1996-01-22 2007-07-17 Boston Scientific Scimed, Inc. Self-sealing PTFE vascular graft and manufacturing methods

Also Published As

Publication number Publication date
CA2186373A1 (fr) 1995-11-09
US5584876A (en) 1996-12-17
JPH09512456A (ja) 1997-12-16
AU2292895A (en) 1995-11-29
EP0757561A1 (fr) 1997-02-12

Similar Documents

Publication Publication Date Title
US5584876A (en) Cell excluding sheath for vascular grafts
Conklin et al. Development and evaluation of a novel decellularized vascular xenograft
US5762600A (en) Blood contact surfaces employing natural subendothelial matrix and methods for making and using the same
Badylak et al. Small intestinal submucosa as a large diameter vascular graft in the dog
US6440166B1 (en) Multilayer and multifunction vascular graft
US5632776A (en) Implantation materials
CA1341519C (fr) Greffe vasculaire
US4687482A (en) Vascular prosthesis
Guidoin et al. In vitro and in vivo characterization of an impervious polyester arterial prosthesis: The Gelseal Triaxial® graft
CN1018893B (zh) 组织移植组合物及其制备方法
CA2074362A1 (fr) Materiel d'implantation
Jordan et al. Gelatin-impregnated Dacron prosthesis implanted into porcine thoracic aorta
Dreyer et al. Aortic grafts of polyurethane in dogs
Pourdeyhimi Vascular grafts: Textile structures and their performance
Watanabe Microarterial prostheses of expanded polytetrafluoroethylene
Huang et al. Cellular reaction to the Vascugraft® polyesterurethane vascular prosthesis: in vivo studies in rats
Nojiri et al. Aorta-coronary bypass grafting with heparinized vascular grafts in dogs: a preliminary study
US10500036B2 (en) Tissue engineering of blood vessels
Rumisek et al. Heat-denatured albumin-coated Dacron vascular grafts: physical characteristics and in vivo performance
Marois et al. In vivo evaluation of hydrophobic and fibrillar microporous polyetherurethane urea graft
Galletti et al. Long-term patency of regenerated neoaortic wall following the implant of a fully biodegradable polyurethane prosthesis: experimental lipid diet model in pigs
Van Der Lei et al. Microarterial grafting into the carotid artery of the rabbit: some considerations concerning species-dependent thrombogenicity
Tsuchida et al. Healing mechanisms of high-porosity PTFE grafts: significance of transmural structure
Pärsson et al. Healing characteristics of polymer-coated or collagen-treated Dacron grafts: an experimental porcine study
Hess et al. Three years experience with experimental implantation of fibrous polyurethane microvascular prostheses in the rat aorta

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2186373

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995916422

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995916422

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995916422

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载